Skip directly to site content Skip directly to search


Here's how you know
 Official websites use .gov A .gov website belongs to an official government organization in the United States.
 Secure .gov websites use HTTPS A **lock** (  ) or **https://** means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.


National Institute for Occupational Safety and Health (NIOSH)
 Explore Topics
 Search
	Clear Input
		Search


For Everyone
 About NIOSH
											Federal Register Notices
											Board of Scientific Counselors
											Events
											Contact
											Careers
											Training and Workforce Development
											Peer Review Agenda
											NIOSH eNews
																View all
 View All


search
                close search Clear Input
		search
 NIOSH Menu
            Close Clear Input
		search
 For Everyone
 About NIOSH
																							Federal Register Notices
																							Board of Scientific Counselors
																							Events
																							Contact
																							Careers
																							Training and Workforce Development
																							Peer Review Agenda
																						View All
																																				Home
 View All
						NIOSH


About NIOSH Federal Register Notices Board of Scientific Counselors Events Contact Careers Training and Workforce Development Peer Review Agenda View All




NIOSH
 Peer Review: List of Hazardous Drugs in Healthcare Settings 2019


Key points
 NIOSH created a peer review plan for the 2019 update of our List of Hazardous Drugs in Healthcare Settings. Healthcare workers who prepare or administer hazardous drugs (e.g., some cancer therapy, antiviral, hormone therapy, and bioengineered agents) may be exposed to these agents in the workplace. Those who work in areas where these drugs are used, such as environmental services workers, may also be exposed.
 Overview Updates‎ Hazardous Drug Exposures in Healthcare
 **Title:** NIOSH List of Hazardous Drugs in Healthcare Settings 2019 (formerly titled NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2018) **Anticipated Date of Dissemination:** December 2019 **Subject:** Hazardous Drug Exposure in Healthcare Settings **Purpose:** To provide healthcare workers and healthcare facilities information on identifying hazardous drugs so that proper handling can be performed to reduce worker exposures. **Type of Dissemination:**Influential Scientific Information **Timing of Review:** September 4, 2017 – October 13, 2017 **Primary Disciplines or Expertise Needed for Review:** toxicology, industrial hygiene, occupational medicine, oncology nursing practices and pharmacy practices **Type of Review:** Individual letters **Number of Reviewers:**4 –  10 **Reviewers Selected by:** CDC/NIOSH **Public Nominations Requested for Review Panel:** No **Opportunities for the Public to Comment:**Yes, Publication of a request for public comments **Peer Reviewers Provided with Public Comments Before Their Review:** No NIOSH will review all individual comments from the peer reviewers and post a list of proposed additions to the Federal Register for public comment. NIOSH will then make decisions about updating the list based on all comments. The proposed changes to the list will then be placed on the NIOSH Docket.
 NIOSH definition of a hazardous drug Carcinogenicity
Teratogenicity or other developmental toxicity*
Reproductive toxicity*
Organ toxicity at low doses*
Genotoxicity**
Structure and toxicity profiles of new drugs that mimic existing drugs determined *All drugs have toxic side effects, but some exhibit toxicity at low doses. The level of toxicity reflects a continuum from relatively nontoxic to production of toxic effects in patients at low doses (for example, a few milligrams or less). For example, a daily therapeutic dose of 10 mg/ day or a dose of 1 mg/kg per day in laboratory animals that produces serious organ toxicity, developmental toxicity, or reproductive toxicity has been used by the pharmaceutical industry to develop occupational exposure limits (OELs) of less than 10 μg/m3after applying appropriate uncertainty factors [Sargent and Kirk 1988; Naumann and Sargent 1997; Sargent et al. 2002]. OELs in this range are typically established for potent or toxic drugs in the pharmaceutical industry. Under all circumstances, an evaluation of all available data should be conducted to protect health care workers. **In evaluating mutagenicity for potentially hazardous drugs, responses from multiple test systems are needed before precautions can be required for handling such agents. The EPA evaluations include the type of cells affected and in vitro versus in vivo testing [51 Fed. Reg. 34006– 34012 (1986)].
 Charge to reviewers The NIOSH Hazardous Drug Committee has reviewed all new FDA drug approvals and new drug warnings for the period January 2014 through December 2015. The committee reviewed 73 new drug approvals and 198 drugs with new warnings. In addition to the drugs identified by the FDA database searches, the NIOSH Director received a request to evaluate two drugs, dihydroergotamine and isotretinoin, for placement on the List by an interested party. NIOSH identified 44 drugs as potentially hazardous for review by the peer reviewers. We are requesting that as a peer reviewer, you review the list of drugs that NIOSH suggests be added to the list or not added to the list and provide your evaluations and comments. General guidance Our goal is to conduct a *hazard identification*. We do not conduct a risk assessment. However, we take into account the dose for animal testing for reproductive and developmental toxicity and carcinogenicity testing. If adverse effects are observed near, at, or below the maximum recommended human dose (MRHD), we consider it to be highly relevant. If doses producing an adverse effect are many time the MRHD, we usually do not consider them in our evaluation. In addition to dose, for carcinogenicity testing we look for tumors in more than one species and sex. We look for tumors in multiple organs and we look for tumors that are not rodent-specific. Any available human data are considered significant. For genotoxicity effects, we look at in vivo testing over in vitro testing. However, adverse outcomes in several in vitro tests may be considered in our evaluation. For reproductive and developmental effects we note if there was maternal toxicity in addition to the dose. Effects on the fetus in the absence of maternal toxicity are considered relevant. Drugs with an FDA pregnancy category X rating are typically listed as hazardous. Drugs in Category D are often listed as hazardous, but it will depend on the individual drug. Any available human data are considered significant. For organ toxicity, the low dose criterion in the definition is used as a benchmark. Drugs with manufacturer's safe handling guidelines are usually put on the list as the manufacturer has decided they are hazardous enough to warrant special handling. Therefore, drugs with manufacturers' safe handling recommendations do not require review. Basis for recommendation A "significant" adverse effect in one of these criteria is usually considered enough to list a drug as hazardous. However, less strong evidence in two or three criteria is sometimes sufficient to list a drug as hazardous. Box labeled "Decision Criteria" Please list the factors that led to your decision of "yes" or "no" to listing as hazardous. Be aware that you CAN indicate that you think a drug should only be listed in Table 3 (reproductive hazard)
 NIOSH response to peer review comments NIOSH requested individual comments from peer reviewers via letters. There was no meeting convened for this review. For each drug, comments from individual peer reviewers are provided in a combined listing format after each of the NIOSH Hazardous Drug criteria. Comments are not attributed to individual peer reviewers. The response to the peer reviewers' comments is provided for each drug and is the rationale for proposing to place or not to place a drug on the List. This determination was made by the NIOSH Hazardous Drugs Committee after consideration of the NIOSH committee's evaluation and the individual peer review comments. See Also: Reviewers' comments and NIOSH's responses
 Peer reviewers Director, Center for Excellence in Risk and Exposure Science and Education, University of Cincinnati
 Assistant Dean of Experiential Learning and Program Assistant Professor, University of Maryland School of PharmacyMedication Safety Officer, Johns Hopkins Hospital
 Byrdine F. Lewis School of Nursing and Health Professions, Georgia State University
 University of Maryland, School of Medicine, Occupational Health Project
 On This Page
	Overview
								NIOSH definition of a hazardous drug
								Charge to reviewers
								NIOSH response to peer review comments
								Peer reviewers
  May 29, 2024 Sources Print Share
 Facebook LinkedIn Twitter Syndicate
 National Institute for Occupational Safety and Health


NIOSH National Institute for Occupational Safety and Health View All
 About NIOSH
													Federal Register Notices
													Board of Scientific Counselors
													Events
													Contact
 Careers
													Training and Workforce Development
													Peer Review Agenda
													NIOSH eNews
																			View All
 Sign up for Email Updates


Contact Us Contact Us Call 800-232-4636
							Contact CDC
 About CDC About CDC Mission & Organization
							Budget & Funding
							Careers & Jobs
 Policies Accessibility
									External Links
									Privacy
									Web Policies
 FOIA
									OIG
									No Fear Act
									Nondiscrimination
									Vulnerability Disclosure Policy
 Languages Languages Español
									Multilingual Content
 Language Assistance Español
											繁體中文
											Tiếng Việt
											한국어
 Tagalog
											Русский
											العربية
											Kreyòl Ayisyen
 Français
											Polski
											Português
											Italiano
 Deutsch
											日本語
											فارسی
											English
 Archive CDC Archive


Contact Us Contact Us  Call 800-232-4636
						Contact CDC
 About CDC Mission & Organization
						Budget & Funding
						Careers & Jobs
						About CDC
 Policies Accessibility
						External Links
						Privacy
						Web Policies FOIA
						OIG
						No Fear Act
						Nondiscrimination
						Vulnerability Disclosure Policy
 Languages Languages Español
						Multilingual Content Language Assistance Español
						繁體中文
						Tiếng Việt
						한국어
						Tagalog
						Русский
						العربية
						Kreyòl Ayisyen
						Français
						Polski
						Português
						Italiano
						Deutsch
						日本語
						فارسی
						English
 Archive CDC Archive





HHS.gov USA.gov